Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Erasca
Biotech
Former Legend CEO lands at K2—Chutes & Ladders
Former Legend CEO lands at K2. VIB-spin off Tanai appoints new CEO. Transition at Bicara ahead of phase 2/3.
Donavyn Coffey
,
Marissa Russo
,
Will Maddox
Aug 14, 2026 8:30am
Erasca hits ‘home run’ with cancer data but stock suffers
Apr 28, 2026 9:50am
Erasca looks to partner off late-stage melanoma asset
May 13, 2025 10:38am
Erasca lays off 18%, swaps out KRAS program for fresh options
May 17, 2024 5:30am
Erasca erases part of pipeline after revealing mixed cancer data
Jun 6, 2023 10:00am
Erasca slides a Novartis melanoma med into pipeline for $20M
Dec 9, 2022 10:50am